Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Introduction: The early suspension of Altitude trial in recent years has induced most nephrologists and cardiologists to abandon Aliskiren use. Consequently, the potential usefulness of the direct renin inhibition in IgA glomerulonephritis remained an under-investigated therapeutic option. Case Report: We report the case of a 53 years old IgA GMN patient unresponsive to all conventional anti-angiotensin-2 agents, steroids and immunosuppressants, in which the administration of Aliskiren permitted to achieve and maintain a complete proteinuria remission in the absence of any adverse event. Conclusion: Aliskiren might represent a valid and safe therapeutic option in IgA GMN, although further investigations would be needed to confirm this conclusion.

Loading

Article metrics loading...

/content/journals/rrct/10.2174/1574887113666180726103648
2019-03-01
2025-09-04
Loading full text...

Full text loading...

/content/journals/rrct/10.2174/1574887113666180726103648
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test